Advertisement

Topics

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 648-page report is available in PDF from $2000.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015’, provides an overview of the Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 19
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 22
Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 26
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 38
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 40
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 129
Drug Profiles 149
Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 432
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 610
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 619
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 621
Appendix 630

For more information open Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015.

SKU: GMDHC6567IDB

Original Article: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...